1-bromo-2-(2-benzyloxyphenyl)ethane | 107607-78-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-bromo-2-(2-benzyloxyphenyl)ethane
• 英文别名: 1-(benzyloxy)-2-(2-bromoethyl)benzene；1-(2-bromoethyl)-2-phenylmethoxybenzene
• CAS: 107607-78-3
• 化学式: C₁₅H₁₅BrO
• 分子量: 291.187
• InChiKey: UBRLHZPGMCOXMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-bromo-2-(2-benzyloxyphenyl)ethane 在 4-二甲氨基吡啶 、 氢氧化钾 、 sodium hydride 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 52.0h， 生成 N-[3-[(2-benzyloxyphenyl)-prop-1-yl]carboxy]succinimide
  参考文献：
  名称：

  Synthesis and physicochemical assessment of novel 2-substituted 3-hydroxypyridin-4-ones, novel iron chelators

  摘要：

  标题：摘要 新型含三齿配体的3-羟基吡啶-4-酮被合成，并对其物理化学性质进行了表征，包括电离常数和与Fe(III)的化学计量滴定。目前急需口服活性铁螯合剂，以潜在治疗地中海贫血。原则上，三齿配体可能比双齿分子更具动力学稳定性，但迄今尚未找到令人满意的分子。通过与六齿配体EDTA竞争评估了Fe(III)的稳定常数。在所有情况下，均未发现三齿铁螯合模式的证据；相反，配体表现为双齿羟基吡啶酮。因此，它们与更简单的烷基羟基吡啶酮相比并无优势。

  DOI：

  10.1211/0022357021778592
• 作为产物：
  描述：

  邻羟基苯乙醇 在 sodium hydroxide 、 四溴化碳 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙腈 为溶剂， 反应 18.0h， 生成 1-bromo-2-(2-benzyloxyphenyl)ethane
  参考文献：
  名称：

  Synthesis and physicochemical assessment of novel 2-substituted 3-hydroxypyridin-4-ones, novel iron chelators

  摘要：

  标题：摘要 新型含三齿配体的3-羟基吡啶-4-酮被合成，并对其物理化学性质进行了表征，包括电离常数和与Fe(III)的化学计量滴定。目前急需口服活性铁螯合剂，以潜在治疗地中海贫血。原则上，三齿配体可能比双齿分子更具动力学稳定性，但迄今尚未找到令人满意的分子。通过与六齿配体EDTA竞争评估了Fe(III)的稳定常数。在所有情况下，均未发现三齿铁螯合模式的证据；相反，配体表现为双齿羟基吡啶酮。因此，它们与更简单的烷基羟基吡啶酮相比并无优势。

  DOI：

  10.1211/0022357021778592

文献信息

• [EN] AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] INHIBITEURS D'AMINOPEPTIDASE A ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：QUANTUM GENOMICS

  公开号：WO2020084131A1

  公开（公告）日：2020-04-30

  The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

  本发明涉及一种新型化合物，包括该化合物的组合物，制备该化合物的方法，以及该化合物在治疗中的应用。具体而言，本发明涉及一种在治疗和预防原发性和继发性动脉高血压、中风、心肌缺血、心脏和肾功能不全、心肌梗死、外周血管疾病、糖尿病蛋白尿、X综合征和青光眼中有用的化合物。
• Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same
  申请人：QUANTUM GENOMICS

  公开号：US11192907B2

  公开（公告）日：2021-12-07

  The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

  本发明涉及一种新型化合物、一种包含该化合物的组合物、制备该化合物的方法以及该化合物在治疗中的应用。特别是，本发明涉及一种可用于治疗和预防原发性和继发性动脉高血压、心肌梗塞、心肌缺血、心肾功能不全、心肌梗塞、外周血管疾病、糖尿病蛋白尿、X综合征和青光眼的化合物。
• Discovery and SAR of a Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B
  作者：Henrik Sune Andersen、Ole H. Olsen、Lars F. Iversen、Anette L. P. Sørensen、Steen B. Mortensen、Michael S. Christensen、Sven Branner、Thomas K. Hansen、Jesper F. Lau、Lone Jeppesen、Edmond J. Moran、Jing Su、Farid Bakir、Luke Judge、Manou Shahbaz、Tassie Collins、Todd Vo、Michael J. Newman、William C. Ripka、Niels Peter H. Møller

  DOI：10.1021/jm0209026

  日期：2002.9.1

  Reversible phosphorylation and dephosphorylation of key proteins on tyrosine residues are important parts of intracellular signaling triggered by hormones and other agents. Recent knock-out studies in mice have identified PTP1B as a potential target for the treatment of diabetes and obesity. As a consequence, a number of academic and industrial groups are aggressively pursuing the development of selective PTP1B inhibitors. In addition, other protein-tyrosine phosphatases (PTPs) appear to be critically involved in major diseases such as cancer and autoimmunity. Given the diversity of PTPs and their potential as drug targets in different diseases, we have taken a broad approach to develop active site-directed selective inhibitors of specific members of this family of enzymes. Using a high throughput screening, we have previously identified 2-(oxalylamino)benzoic acid 3a as a relatively weak but classical competitive inhibitor of several PTPs.(4) On the basis of our early studies, indicating that 3a might be used as a starting point for the synthesis of selective PTP inhibitors, we now present our efforts in expansion of this concept and provide here a number of new chemical scaffolds for the development of inhibitors of different members of the PTP family. Although the core structure of these inhibitors is charged, good oral bioavailability has been observed in rat for some compounds. Furthermore, we have observed enhancement of 2-deoxy-glucose accumulation in C2C12 cells with prodrug analogues.
• ARIMA, HIDEKI;TAMAZAWA, KAZUHARU, J. LABELLED COMPOUNDS AND RADIOPHARM., 1985, 22, N 12, 1217-1226
  作者：ARIMA, HIDEKI、TAMAZAWA, KAZUHARU

  DOI：——

  日期：——
• AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：QUANTUM GENOMICS

  公开号：US20210309678A1

  公开（公告）日：2021-10-07

  The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.